Navigation Links
Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
Date:3/31/2009

SYDNEY, March 31 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced completion of the first component of its Phase III international trial assessing the effectiveness of Bronchitol in people with cystic fibrosis.

The final subject has now completed their final clinical visit and the trial has run to time and budget. The first subject entered the trial in April 2007.

The trial was conducted in 40 centres in four different countries and involved 325 randomized subjects with cystic fibrosis. The trial was a double blind, placebo controlled study designed with the assistance of the European regulatory agency (EMEA) and with the objective of seeking a marketing approval for Bronchitol for treating cystic fibrosis in Europe and elsewhere.

The results of the trial are expected to be available later this month after data review and statistical analysis of the various endpoints have been completed. The first objective of the trial is to demonstrate an improvement in lung function. Consistent loss of lung function is the leading cause of death of people with cystic fibrosis.

Dr Alan Robertson, Pharmaxis Chief Executive Officer said: "We are very pleased to announce this major milestone for Pharmaxis and look forward to the results of the study with great interest. It is hoped Bronchitol will change the therapeutic landscape for people living with cystic fibrosis and provide a new therapeutic regimen that helps to prolong life."

The second component of the trial will examine the safety of Bronchitol in people with cystic fibrosis.

Pharmaxis has received Orphan Drug Designation and fast track status from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency for Bronc
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
2. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Pharmaxis Establishes Named Patient Program for Bronchitol
5. Pharmaxis Long-Term Safety Study of Bronchitol Completes
6. Schering-Plough Announces Results of the Early ACS Trial
7. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
8. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
9. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
10. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the ... Estimates and Forecasts, 2012-2018"  report to their offering. ... by 2016. The North America ... while Europe claims approximately 25% ...
(Date:12/15/2014)... and HERZLIYA PITUACH, Israel , Dec. ... IMNP ) announced today that its Board of ... succeeding Dr. Daniel Teper who continues as Chief ... of Immune,s Board of Directors since 2013. Immune,s ... delighted to represent the interest of shareholders and to continue ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014   ... SAN and NYSE: SNY) are collaborating with nationally-recognized patient ... Counts , an awareness program that will gauge how ... risks associated with high LDL-C (bad cholesterol).  American adults ... to take a brief poll and answer a few ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... moms who were exposed to high levels of air pollution ... autism, a U.S. study suggests. Researchers found that of ... 2002, those exposed to the most air pollution during pregnancy ... developed autism. And exposure during the third trimester, specifically, showed ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- Prostaglandin analogue eye drops ... reduce the risk of vision loss in patients with ... researchers led by David Garway-Heath, of the Moorfields Eye ... outcomes for more than 500 people newly diagnosed with ... disease and one of the leading causes of blindness. ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 17, 2014 HeartMath® Inc., recognized ... stress, heart rate variability (HRV), heart coherence and ... extensive HRV databases and algorithms to chipset manufacturers ... enable HeartMath’s partners to offer its HRV solutions, ... as well as its normative HRV databases and ...
(Date:12/17/2014)... 2014 No matter how far modern ... eradicate the head louse parasite—a common childhood malady and ... year between six and twelve million individuals will suffer ... removal treatment company comes to the rescue, providing an ... With its track record of customer service, and effectiveness ...
Breaking Medicine News(10 mins):Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... Personal Protective Equipment Conference 2009 (PPE 2009), which ... in Fort Lauderdale, FL, November 17 - 19, 2009, ... networking resource for firefighters, law enforcement officers, military personnel, ... technicians, veterinary specialists, rescue team members, and other first ...
... , , ... supporting breast cancer research and awareness programs, Hard Rock International ... )winner, breast cancer survivor and multi-platinum recording artist, as its ... PINKTOBER program will also be ...
... , , Atlanta to Serve as ... NEW YORK , Sept. 14 ... the Center for AIDS Research at Emory University (CFAR) in Atlanta, Georgia will ... global scientific conference focused on AIDS vaccine research. AIDS 2010 is to ...
... for Down syndrome on the horizon promising to be safer, ... medical community must come together and engage in dialogue about ... leading article published Online First by Archives of Disease ... genetics fellow at Children,s Hospital Boston, the article shows a ...
... SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: ... has entered into a strategic relationship with Allscripts (NASDAQ: ... (e-prescribing) options available to SXC,s healthcare benefits management customers. ... plans, employers, government agencies, pharmacy benefit managers and pharmacies ...
... Sept. 14 A call for participants has been issued in ... upon the work the IMIA started in the 1980s with the ... final written exam pilot in support of national certification. , ... and rating of test items have been finalized, it is important ...
Cached Medicine News:Health News:Personal Protective Equipment Conference Set for November 17 - 19 in Fort Lauderdale 2Health News:Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER(TM) Campaign Featuring Melissa Etheridge, The Bangles, Melanie C, Joss Stone And More 2Health News:Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER(TM) Campaign Featuring Melissa Etheridge, The Bangles, Melanie C, Joss Stone And More 3Health News:Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER(TM) Campaign Featuring Melissa Etheridge, The Bangles, Melanie C, Joss Stone And More 4Health News:Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 2Health News:Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 3Health News:Center for AIDS Research at Emory University to Serve as Local Host of AIDS Vaccine 2010 4Health News:Understanding the implications of prenatal testing for Down syndrome 2Health News:SXC Health Solutions teams with Allscripts to deliver critical prescription information to physicians at the point-of-care 2Health News:SXC Health Solutions teams with Allscripts to deliver critical prescription information to physicians at the point-of-care 3Health News:SXC Health Solutions teams with Allscripts to deliver critical prescription information to physicians at the point-of-care 4Health News:SXC Health Solutions teams with Allscripts to deliver critical prescription information to physicians at the point-of-care 5Health News:National Certification for Medical Interpreters - Public Call for Final Written Pilot Exam 2
Measles IgM ELISA....
Toxo IgG ELISA. All Wampole ELISA kits include the following: 12 x 8 well strips with breakaway wells, sample diluent, controls and calibrators, conjugate, TMB substrate, wash buffer, stop solution,...
ELISA kit for CMV CAP M....
Cytomegalovirus IgM ELISA....
Medicine Products: